filgrastim for Breast Cancer

"According to the stated restrictions, individuals must be between 18-59 years of age in order to qualify for this medical trial."

"As this is only a Phase 1 trial, which lacks evidence of safety and efficacy according to our team at Power, filgrastim received the lowest score possible-1."

"Since its initial study in 1997, sponsored by Alfacell and involving 300 participants, filgrastim has enjoyed a remarkable amount of research. Presently there are 1759 active studies conducted across 3488 cities and 82 countries concerning this medication's efficacy. Following the first trial in '97, it was granted Phase 3 drug approval."

"Per the clinicaltrials.gov website, this particular medical trial is no longer in need of participants; its initial posting was on May 18th 1999 and it's been updated as recently as February 17th 2022. Despite that, there are still 4359 other trials actively recruiting at this time."

"This medical trial is searching for 15 individuals with breast cancer, aged 18 to 59 years-old. It is essential that they meet the following criteria: Disease Characteristics - histologically verified instance of Stage IV metastatic cancer responding well to prior chemotherapy or high risk primary disease; Patient Characteristics - between eighteen and fifty nine, Karnofsky Performance Status 80%-100%; Life expectancy not specified; Hematopoietic/Hepatic/Renal parameters as noted in above text; Cardiovascular no prior valvular heart illness or arrhythmia; Pulmonary conditions according to given information. Additionally, applicants must have completed"

"filgrastim is frequently utilized for the management of leukemia, but can also be efficacious in treating metastatic bladder cancer and non-small cell lung cancers."

"This research trial is not currently accepting patients. Initially posted on May 18th, 1999 and last modified February 17th 2022, it cannot be used to join a study at this time. Alternatives can be found through 2600 studies that admit participants with breast cancer or the 1759 trials actively recruiting for filgrastim treatments."